Eliem Therapeutics, Inc. ELYM
We take great care to ensure that the data presented and summarized in this overview for Eliem Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ELYM
View all-
Ra Capital Management, L.P. Boston, MA13.2MShares$108 Million0.53% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.19MShares$17.9 Million4.02% of portfolio
-
Driehaus Capital Management LLC Chicago, IL812KShares$6.64 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA310KShares$2.54 Million0.0% of portfolio
-
Atom Investors LP Austin, TX78.3KShares$640,2970.03% of portfolio
-
Geode Capital Management, LLC Boston, MA66.6KShares$545,0000.0% of portfolio
-
Bridgeway Capital Management, LLC Houston, TX55.2KShares$451,7240.0% of portfolio
-
Northern Trust Corp Chicago, IL43.5KShares$355,5680.0% of portfolio
-
Black Rock Inc. New York, NY30.4KShares$248,9990.0% of portfolio
-
Paul Tudor Jones Tudor Investment Corp Et Al | Stamford, Ct29.5KShares$241,0310.0% of portfolio
Latest Institutional Activity in ELYM
Top Purchases
Top Sells
About ELYM
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Insider Transactions at ELYM
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 05
2024
|
Valerie Morisset EVP, R&D AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,847
+3.41%
|
-
|
|
Sep 20
2023
|
Valerie Morisset EVP, R&D AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,728
+2.09%
|
-
|
|
Mar 10
2023
|
Valerie Morisset EVP, R&D AND CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
316,410
+25.11%
|
-
|
|
Aug 12
2021
|
Ai Eti LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,000
+13.77%
|
$9,600,000
$12.5 P/Share
|
|
Aug 12
2021
|
Ai Eti LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,209,400
+50.0%
|
-
|
|
Aug 12
2021
|
Ra Capital Management, L.P. Director |
BUY
Conversion of derivative security
|
Indirect |
6,867,517
+45.25%
|
-
|
|
Aug 12
2021
|
Ra Capital Management, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
3,200,000
+25.42%
|
$38,400,000
$12.5 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 38.6K shares |
|---|